SI1627639T1 - Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj - Google Patents
Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenjInfo
- Publication number
- SI1627639T1 SI1627639T1 SI200230890T SI200230890T SI1627639T1 SI 1627639 T1 SI1627639 T1 SI 1627639T1 SI 200230890 T SI200230890 T SI 200230890T SI 200230890 T SI200230890 T SI 200230890T SI 1627639 T1 SI1627639 T1 SI 1627639T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cox
- inhibitors
- treatment
- affective disorders
- affective
- Prior art date
Links
- 208000019022 Mood disease Diseases 0.000 title 1
- 229940111134 coxibs Drugs 0.000 title 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129320A DE10129320A1 (de) | 2001-06-19 | 2001-06-19 | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| US36490402P | 2002-03-14 | 2002-03-14 | |
| EP05024864A EP1627639B1 (en) | 2001-06-19 | 2002-05-31 | Use of COX-2 inhibitors for the treatment of affective disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1627639T1 true SI1627639T1 (sl) | 2010-04-30 |
Family
ID=26009543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200230890T SI1627639T1 (sl) | 2001-06-19 | 2002-05-31 | Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040204469A1 (https=) |
| EP (2) | EP1397145B1 (https=) |
| JP (2) | JP4205577B2 (https=) |
| AP (1) | AP1512A (https=) |
| AT (2) | ATE452642T1 (https=) |
| AU (1) | AU2002312967A1 (https=) |
| CA (1) | CA2448025C (https=) |
| CY (1) | CY1109949T1 (https=) |
| DE (2) | DE60234873D1 (https=) |
| DK (2) | DK1397145T3 (https=) |
| EA (1) | EA009780B1 (https=) |
| ES (2) | ES2271269T3 (https=) |
| OA (1) | OA12627A (https=) |
| PT (2) | PT1627639E (https=) |
| SI (1) | SI1627639T1 (https=) |
| WO (1) | WO2002102297A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| WO2004047844A1 (en) * | 2002-11-26 | 2004-06-10 | Alexza Pharmaceuticals, Inc. | Use of loxapine and amoxapine for the manufacture of a medicament for the treatment of pain |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| MXPA05012391A (es) * | 2003-05-16 | 2006-02-02 | Pfizer Prod Inc | Tratamiento de trastornos psicoticos y depresivos. |
| EP1625333A1 (en) | 2003-05-21 | 2006-02-15 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
| CA2536161A1 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| EP1687000A2 (en) * | 2003-11-19 | 2006-08-09 | Glaxo Group Limited | Use of cyclooxygenase-2 inhibitors for the treatment of depressive disorders |
| EP1687001A2 (en) * | 2003-11-19 | 2006-08-09 | Glaxo Group Limited | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| JP2007526328A (ja) * | 2004-03-02 | 2007-09-13 | ファルマシア コーポレーション | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| EP2246086A3 (en) | 2004-08-12 | 2012-11-21 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heating unit |
| US20070281927A1 (en) * | 2006-06-06 | 2007-12-06 | Shanthakumar Tyavanagimatt | Anti-inflammatory and analgesic compositions and related methods |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| JP5144104B2 (ja) | 2007-04-09 | 2013-02-13 | ユニ・チャーム株式会社 | 伸縮性複合シート及びそれを用いた使い捨て着用物品 |
| EP2485744A4 (en) * | 2009-10-09 | 2014-01-22 | Prothera Inc | COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED |
| EP2340819A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising venlafaxine and celecoxib in the treatment of pain |
| EP2340818A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of venlafaxine and celecoxib |
| AU2018378348B2 (en) | 2017-12-05 | 2024-09-19 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| EP3746138B1 (en) | 2018-02-02 | 2025-12-10 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
| AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4564614A (en) * | 1984-10-11 | 1986-01-14 | Pfizer Inc. | Antiinflammatory methods |
| AU1041599A (en) * | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
| US6465458B1 (en) * | 1999-07-01 | 2002-10-15 | Pharmacia & Upjohn Company | Method of treating or preventing chronic pain with a highly selective norepinephrine reuptake inhibitor |
| EP1142889A1 (en) * | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
| US6306842B1 (en) * | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
-
2002
- 2002-05-31 EA EA200301291A patent/EA009780B1/ru not_active IP Right Cessation
- 2002-05-31 DK DK02738138T patent/DK1397145T3/da active
- 2002-05-31 JP JP2003504886A patent/JP4205577B2/ja not_active Expired - Fee Related
- 2002-05-31 US US10/480,600 patent/US20040204469A1/en not_active Abandoned
- 2002-05-31 EP EP02738138A patent/EP1397145B1/en not_active Expired - Lifetime
- 2002-05-31 EP EP05024864A patent/EP1627639B1/en not_active Expired - Lifetime
- 2002-05-31 ES ES02738138T patent/ES2271269T3/es not_active Expired - Lifetime
- 2002-05-31 AU AU2002312967A patent/AU2002312967A1/en not_active Abandoned
- 2002-05-31 AT AT05024864T patent/ATE452642T1/de active
- 2002-05-31 DE DE60234873T patent/DE60234873D1/de not_active Expired - Lifetime
- 2002-05-31 PT PT05024864T patent/PT1627639E/pt unknown
- 2002-05-31 AT AT02738138T patent/ATE338557T1/de active
- 2002-05-31 DK DK05024864.0T patent/DK1627639T3/da active
- 2002-05-31 DE DE60214542T patent/DE60214542T2/de not_active Expired - Lifetime
- 2002-05-31 WO PCT/EP2002/006013 patent/WO2002102297A2/en not_active Ceased
- 2002-05-31 ES ES05024864T patent/ES2336682T3/es not_active Expired - Lifetime
- 2002-05-31 AP APAP/P/2003/002934A patent/AP1512A/en active
- 2002-05-31 CA CA2448025A patent/CA2448025C/en not_active Expired - Fee Related
- 2002-05-31 OA OA1200300328A patent/OA12627A/en unknown
- 2002-05-31 SI SI200230890T patent/SI1627639T1/sl unknown
- 2002-05-31 PT PT02738138T patent/PT1397145E/pt unknown
-
2008
- 2008-07-22 JP JP2008188890A patent/JP4824727B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-22 CY CY20101100270T patent/CY1109949T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE452642T1 (de) | 2010-01-15 |
| DK1627639T3 (da) | 2010-04-26 |
| JP2004534066A (ja) | 2004-11-11 |
| JP4205577B2 (ja) | 2009-01-07 |
| DE60214542D1 (de) | 2006-10-19 |
| EP1627639A2 (en) | 2006-02-22 |
| CA2448025C (en) | 2011-07-05 |
| OA12627A (en) | 2006-06-13 |
| PT1397145E (pt) | 2006-10-31 |
| AU2002312967A1 (en) | 2003-01-02 |
| EA200301291A1 (ru) | 2004-06-24 |
| DE60214542T2 (de) | 2006-12-21 |
| EP1397145B1 (en) | 2006-09-06 |
| CA2448025A1 (en) | 2002-12-27 |
| EP1627639B1 (en) | 2009-12-23 |
| DK1397145T3 (da) | 2007-01-02 |
| AP2003002934A0 (en) | 2003-12-31 |
| PT1627639E (pt) | 2010-03-01 |
| CY1109949T1 (el) | 2014-09-10 |
| ES2271269T3 (es) | 2007-04-16 |
| WO2002102297A3 (en) | 2003-05-01 |
| ATE338557T1 (de) | 2006-09-15 |
| EP1627639A3 (en) | 2006-09-27 |
| US20040204469A1 (en) | 2004-10-14 |
| EA009780B1 (ru) | 2008-04-28 |
| JP2008297308A (ja) | 2008-12-11 |
| EP1397145A2 (en) | 2004-03-17 |
| DE60234873D1 (de) | 2010-02-04 |
| AP1512A (en) | 2005-12-15 |
| JP4824727B2 (ja) | 2011-11-30 |
| ES2336682T3 (es) | 2010-04-15 |
| WO2002102297A2 (en) | 2002-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1627639T1 (sl) | Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj | |
| IL209842A0 (en) | Compounds for the treatment of metabolic disorders | |
| IL160389A0 (en) | Use of flibanserin for the treatment of sexual disorders | |
| ZA200401004B (en) | Combination for the treatment of inflammatory disorders | |
| AU2003286567A8 (en) | Methods for the treatment of skin disorders | |
| PT1531819E (pt) | Utilização de inibidores da i capa b cinase na terapia da dor | |
| PL378108A1 (pl) | Leczenie łączone do terapii zapalnych zaburzeń immunologicznych | |
| AU2003300791A1 (en) | Combination therapy for the treatment of pain | |
| IL162485A0 (en) | Compounds for the treatment of inflammatory disorders | |
| IL161267A0 (en) | Combinations for the treatment of immunoinflammatory disorders | |
| PT1487828E (pt) | Derivados de morfolinil-ureia para utilização no tratamento de doenças inflamatórias | |
| IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
| HUP0303306A3 (en) | Use of il-18 inhibitors for the treatment and/or prevention of heart disease | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
| AU2003266965A1 (en) | Use of carboxamides for the treatment of tinnitus | |
| IL175412A0 (en) | Use of specific histones for the treatment of parasitic diseases | |
| IL162053A0 (en) | Method for the treatment of bone disorders | |
| ZA200505996B (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
| GB2388027B (en) | Use of palatinose for the treatment of mental stress | |
| AU2002354698A1 (en) | Use of xaa-pro peptidases for the treatment of substance p-related disorders | |
| HRP20041159A2 (en) | Combination for the treatment of airway disorders | |
| GB0216097D0 (en) | Treatment of proliferative disorders | |
| PL370839A1 (en) | Use of proton pump inhibitors for the treatment of airway disorders | |
| AU2003294697A8 (en) | Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain |